In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604.
Keywords: fungal infection; fungal treatment; obese; optimal dosing; population pharmacokinetics.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.